title: Immunomodulation and lymphoma in humans.
abstract: Observational and clinical studies have associated increased cancer risks with primary or acquired immunodeficiencies, autoimmunity, and use of immunotherapies to treat chronic inflammation (e.g. autoimmunity) or support organ engraftment. Understanding of the relationship between immune status and cancer risk is generally grounded in two juxtaposing paradigms: that the immune system protects the host via surveillance of tumors and oncogenic viruses (e.g. immunosurveillance model) and that chronic inflammation can augment tumor growth and metastasis (inflammation model). Whereas these models support a role of immune status in many cancers, they are insufficient to explain the disproportionate increase in B-cell lymphoma risk observed across patient populations with either chronic immunosuppression or inflammation. Evaluation for the presence of Epstein-Barr virus (EBV) in lymphomas obtained from various populations demonstrates a variable role for the virus in lymphomagenesis across patient populations. An evaluation of the DNA alterations found in lymphomas and an understanding of B-cell ontogeny help to provide insight into the unique susceptibility of lymphocytes, primarily B-cells, to oncogenic transformation. EBV-independent B-cell oncogenic transformation is driven by chronic antigenic stimulation due to either inflammation (as seen in patients with autoimmune disease or a tissue allograft) or to unresolved infection (as seen in immunosuppressed patients), and the transformation arises as a result of DNA damage from genomic recombination and mutation during class switching and somatic hypermutation. This model explains the increased background rate of lymphoma in some patients with autoimmunity, and highlights the challenge of resolving the confounding that occurs between disease severity and use of targeted immunotherapies to treat chronic inflammation. The ability to distinguish between disease- and treatment-related risk of lymphoma and an appreciation of the etiology of B-cell transformation is central to an improved risk assessment by scientists, clinicians and regulators, including the approval, labeling, and chronic use of immunotherapies.
authors.affiliation: Amgen, Inc , Seattle, WA , USA .
authors.forename: Rafael A
authors.initials: RA
authors.lastname: Ponce
authors.forename: Thomas
authors.initials: T
authors.lastname: Gelzleichter
authors.forename: Helen G
authors.initials: HG
authors.lastname: Haggerty
authors.forename: Shawn
authors.initials: S
authors.lastname: Heidel
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Holdren
authors.forename: Herve
authors.initials: H
authors.lastname: Lebrec
authors.forename: R Daniel
authors.initials: RD
authors.lastname: Mellon
authors.forename: Marc
authors.initials: M
authors.lastname: Pallardy
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology* / Q000821:virology; D002471:Cell Transformation, Neoplastic; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000276:immunology / Q000628:therapy*; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host; D056747:Immunomodulation; D007167:Immunotherapy / Q000379:methods*; D016393:Lymphoma, B-Cell / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D018570:Risk Assessment